Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9402-26-Q-9303
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Department of Defense, through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-26-Q-9303) seeking quotations from qualified pharmaceutical manufacturers for participation in the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP). This procurement is mandated by 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21), which require the establishment of an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). The program’s primary objective is to ensure the availability of clinically effective and cost-efficient pharmaceutical agents to military beneficiaries.
The scope of this solicitation encompasses the acquisition of pharmaceutical agents within specific drug classes identified for potential placement on the DoW Uniform Formulary (UF). The Pharmacy and Therapeutics (P&T) Committee will review the clinical and cost effectiveness of these agents, considering their classification for cost-sharing purposes as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). The outcome of this process will inform the award of UF BPAs and UF ADP agreements, which are designed to secure favorable pricing and access for the MHS.
For the August 2026 P&T Committee meeting, the following newly approved drugs will be reviewed for potential inclusion in the UF:
- Bysanti (Antipsychotic Agents – Atypical)
- Idvynso (Antiretrovirals – Combinations)
- Nereus (Antiemetic-Antivertigo Agents)
- Zolymbus (Glaucoma Agents – Prostaglandin)
Interested offerors are required to review the attached Request for Quotation (RFQ), which includes detailed instructions, important deadlines, and appendices related to the UF BPA and UF ADP. A pre-quotation teleconference is scheduled for June 10, 2026, as outlined in Part 2.4 of the RFQ. Offerors must submit responses to clinical questions specified in Part 3.4 via email to the designated points of contact by the deadline indicated in Part 2.3.2.
Key requirements for this opportunity include:
- Demonstrated capability in pharmaceutical preparation manufacturing, as classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022).
- Ability to provide competitive pricing and additional discounts as part of the UF ADP.
- Compliance with all regulatory and programmatic requirements set forth by the DoW and DHA.
The place of performance for this procurement is Texas, United States. The contracting activity is managed by the Defense Health Agency, a federal office under the Department of Defense. The primary point of contact for this solicitation is Julia Trang ([email protected]), with secondary support provided by Stephanie Erpelding (dha.san-antonio-tx.acquis-procure.mbx.pharmacy-support@health.mil).
This solicitation is currently active, with a response deadline of June 29, 2026, at 17:06. Interested parties are encouraged to review the full RFQ and associated attachments, available via the official SAM.gov opportunity listing (Opportunity ID: f95ff7e82f68478aa42056344f8c0479), to ensure compliance with all submission requirements and to assess alignment with their organizational capabilities.
Contractors considering this opportunity should note that the core elements—such as the focus on pharmaceutical agents for the MHS, the regulatory framework, and the structured review and selection process—will remain consistent throughout the contract lifecycle. Participation in this program offers the potential for long-term engagement with the DoW pharmacy benefits program and access to a significant federal customer base.
Documents7